Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
IGM Biosciences, Inc. (IGMS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors"
10/02/2023 144 Form 144 - Report of proposed sale of securities:
08/03/2023 8-K Quarterly results
Docs: "IGM Biosciences Announces Second Quarter 2023 Financial Results – Continued progress in clinical development across portfolio – – Public equity offering and concurrent private placement with gross proceeds of $120.0 million – MOUNTAIN VIEW, Calif., August 3, 2023"
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/19/2023 SC 13D/A Topsoe Holding A/S reports a 32.2% stake in IGM Biosciences, Inc.
07/07/2023 D Form D - Notice of Exempt Offering of Securities:
06/28/2023 SC 13D/A Redmile Group, LLC reports a 9.9% stake in IGM Biosciences, Inc.
06/28/2023 SC 13D/A BAKER BROS. ADVISORS LP reports a 10% stake in IGM Biosciences, Inc.
05/12/2023 8-K Quarterly results
Docs: "IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update – Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444 plus FOLFIRI, with and without bevacizumab, in the middle of 2023 – – Plans to begin clinical testing of imvotamab in severe systemic lupus erythematosus and severe rheumatoid arthritis – MOUNTAIN VIEW, Calif., May 12, 2023"
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/21/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year  Interactive Data
Docs: "AMENDED AND RESTATED BYLAWS OF"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 7.6% stake in IGM BIOSCIENCES INC
01/06/2023 8-K Investor presentation
Docs: "M 2 BINDING SITES 10 BINDING SITES"
11/15/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/03/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/03/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/05/2022 SC 13D/A Redmile Group, LLC reports a 11.6% stake in IGM Biosciences, Inc.
08/08/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/08/2022 8-K Quarterly results
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/24/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
05/09/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/27/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/05/2022 SC 13D/A BAKER BROS. ADVISORS LP reports a 11.6% stake in IGM Biosciences, Inc.
04/05/2022 SC 13D/A Redmile Group, LLC reports a 12.9% stake in IGM Biosciences, Inc.
03/30/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, among IGM Biosciences, Inc. and the Representatives",
"Opinion of Wilson Sonsini Goodrich & Rosati",
"IGM Announces Proposed Public Offering",
"IGM Announces Pricing of $200.0 Million Public Offering"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy